Open Access

[Corrigendum] Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression

  • Authors:
    • Ali Kadivar
    • Mohamed Ibrahim Noordin
    • Arya Aditya
    • Behnam Kamalidehghan
    • Ehsan Taghizadeh Davoudi
    • Reihaneh Sedghi
    • Hamid Akbari Javar
  • View Affiliations

  • Published online on: March 4, 2019     https://doi.org/10.3892/ijmm.2019.4119
  • Pages: 2259-2259
  • Copyright : © Kadivar et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Int J Mol Med 14: [Related article:] 414–424, 2018; DOI: 10.3892/ijmm.2018.3590

An interested reader drew to our attention that the above study appeared to contain a high level of overlap with an article by the same authors published in the journal Drug Design, Development and Therapy [Kadivar A, Kamalidehghan B, Akbari Javar H, Karimi B, Sedghi R and Noordin MI: Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes. Drug Des Devel Ther 11: 469-481, 2017]. Following an internal investigation and also in liaison with the authors, it was established that, although the studies were conducted along broadly similar lines, the papers contained entirely different data involving two different subsets of cell lines; the submission to Drug Des Devel Ther aimed to explore the effects of imatinib mesylate on three different groups, with each group being represented by a cell line, whereas the submission to Int J Mol Med explored the effectiveness of imatinib mesylate in breast cancer cell lines. In spite of this, considering the relatedness of the articles and the fact that the paper to Drug Des Devel Ther was submitted first and published while the Int J Mol Med paper was passing through the peer-review process, the authors concede that they should have properly referenced their paper submitted to Drug Des Devel Ther in the Int J Mol Med paper. Note that the publishers of Drug Des Devel Ther, with whom we were liaising, agreed with the decision to issue a Corrigendum for this paper that acknowledges the article published in Drug Des Devel Ther.

The authors regret their failure to acknowledge the related paper in this instance, and apologize to the readership for this oversight.

Related Articles

Journal Cover

May-2019
Volume 43 Issue 5

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kadivar A, Noordin MI, Aditya A, Kamalidehghan B, Davoudi ET, Sedghi R and Javar HA: [Corrigendum] Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression. Int J Mol Med 43: 2259-2259, 2019.
APA
Kadivar, A., Noordin, M.I., Aditya, A., Kamalidehghan, B., Davoudi, E.T., Sedghi, R., & Javar, H.A. (2019). [Corrigendum] Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression. International Journal of Molecular Medicine, 43, 2259-2259. https://doi.org/10.3892/ijmm.2019.4119
MLA
Kadivar, A., Noordin, M. I., Aditya, A., Kamalidehghan, B., Davoudi, E. T., Sedghi, R., Javar, H. A."[Corrigendum] Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression". International Journal of Molecular Medicine 43.5 (2019): 2259-2259.
Chicago
Kadivar, A., Noordin, M. I., Aditya, A., Kamalidehghan, B., Davoudi, E. T., Sedghi, R., Javar, H. A."[Corrigendum] Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression". International Journal of Molecular Medicine 43, no. 5 (2019): 2259-2259. https://doi.org/10.3892/ijmm.2019.4119